Nā papa papa Rosulip: nā ʻōlelo aʻoaʻo a me nā loiloi hoʻomanawanui

Loaʻa ʻia ʻo Rosulip i nā papa ʻaina biconvex, keʻokeʻo a ʻokoʻa paha ke keʻokeʻo i ka waihoʻoluʻu, ʻo ke kōpana ma ke ʻano o kahi kiʻi ʻoniʻoni, ma ka ʻaoʻao kekahi i ka kahakaha "E", ma kēlā ʻaoʻao - "591" (dosage 5 mg), "592" (dosage 10 mg ), "593" (ka lō o 20 mg), "594" (kaʻuʻu o 40 mg). Hoʻopili ʻia kēia mau papa i poli no 7 mau ʻāpana, ma kahi ʻahala kāleka aia nā 2, 4 a me 8 mau laka.

Pharmacodynamics a me ka pharmacokinetics

ʻO Rosuvastatin ma ke ʻano he mea hana maʻamau he hapili pūpū hoʻoneʻe ponoʻī HMG-CoA hoʻohioloka mea e kāohi ai i ka huli ʻana o 3-hydroxy-3-methylglutaryl CoA i mevalonate- mea i hoʻolaha mua ʻia kolamu.

Ma muli o ka hoʻonui nui o ka nui o ka mea LDL e hopu ai i nā hepatocytes ma lalo o ka mana o rosuvastatinhoʻonui ʻia ke pāmiʻi ʻana a me ka catabolism o LDL, a paʻa nō nā hana synthetic lipoproteinsnā haʻahaʻa haʻahaʻa loa i loko o ka ate. Eia kekahi, ʻo ka rosuvastatin kahi hopena koʻikoʻi i ka hopena o nā ʻōhua biochemical e like me:

hoʻonui ka ʻike kolamua me ka ʻike lipoproteins kiʻekiʻe kiʻekiʻe (abbr. Xs - HDL),
ho'ēmi i ka hoihoi 'ana o ka huina kolamume triglycerides,
hoʻemi i ka hoʻoweliweli ʻana apolipoprotein B(APOB), triglyceridesaoiaʻe lipoproteinshaʻahaʻa haʻahaʻa loa (abbr. TG-VLDLP),
hoʻonui i nā ʻike apolipoprotein A-I (APOA-I),.
hōʻemi i nā kiʻekiʻe kiʻekiʻe kolamume lipoproteins haʻahaʻa haʻahaʻa (abbr. Xs - LDL), kolamua kahore-HDL(Xc - ʻaʻole-HDL) kolamume lipoproteins haʻahaʻa haʻahaʻa (Xc - VLDLP), a me kā lākou māhele, i hōʻike ʻia: Xc - LDL / Xc - HDL, ka nui. Xc / Xc - HDL, Xc - non-HDL / Xc - HDL, APOV / APOA-I.

ʻO ka maʻamau, hiki i ka hopena therapeutic ke hopena i loko o ka hebedoma, a ma hope o 2 mau pule o ka maʻi lapaʻau, hiki ke loaʻa ka pae haʻahaʻa o ka nui o 90 paha o ka nui o ka hiki. No ka hoʻokō ʻana i ka hopena kūpono loa, pono ʻoe i 4 mau wiki o ka lapaʻau, a hoʻomau i ka mālama i kahi ʻano maʻamau.

Ka hoʻokūkū piha plasma rosuvastatinme ka hoʻokele waha ʻana i loaʻa ma hope o 5 mau hola. ʻO ka pae o ka bioavailability kūʻokoʻa a hiki i 20% (hoʻonui i ka hoʻohālikelike i ka lāʻau). RosuvastatinI ka ulu ʻana o ke kōʻai hohonu ʻana ma ka ʻōpio, a laila puka i loko o ke kāpili ʻana o ka ʻala a me ka LDL-C i waho. Ma kahi o 90% o ka mea hana ikaika e hoʻopili ai i nā protein i loko o ke kaila koko (ma mua. albumin).

Hāpai rosuvastatin: me he substrate ole-teras hiki i nā mea kikowaena(nui CYP2C9) helei Htoi P450, ke hana nui nei nā metabolites N-desmethyl rosuvastatinpili ʻole lactone nā metabolites.

Ma kahi o 90% o nā loli i loli ʻole rosuvastatinhoʻopau ʻia ma o nā ʻōpū, 5% o ka pākia e nā keiki. ʻO ka hoʻopauʻana i ka hapalua o ke ola he 19 mau hola, me ka piʻi o ka nui o ka nui o ka nui.

Nā hōʻailona no ka hoʻohana ʻana

ʻano IIa e like me ka helu o Fredrickson mahelehypercholesterolemiaʻano IIbhuiia hypercholesterolemia (ma kahi o ke mea ʻai),
i ka hui me nā mea ʻaia me nā ʻano lāʻau ʻē aʻe e hiki ai ke hoʻohaʻahaʻa i nā lipids koko (e.g. apheresis o LDL) me kāna hoʻoilina maʻiʻo homozygous,
ʻano IV e like me ka helu o Fredrickson hypertriglyceridemiahe hoʻohui i mea ʻai,
i ka hui me nā mea ʻaia me nā maʻi e hoʻemi ana i ka pae o ka nui. Xs, Xs-LDL e lohi i ka holomua atherosclerosis,
no ka pale ʻana o nā hoʻopiʻi ʻano like ʻole o nā ʻano puʻuwai, ʻo ia hoʻi: myocardial infarction, he poho, hoʻihoʻi ʻia arterial me ka ʻole o nā hōʻike pilikino, akā me ka mahuahua o ka ulu ʻana o ka hoʻolālā maʻi maʻi coronaryi ka ihu o nā hopena pilikia e like me haehae maʻi, haʻahaʻa HDL-C, ulaula, ka hele ʻana i ka moʻolelo o ka ʻohana o ka hoʻomaka ʻana o ka maʻi ischemic.

Nā Hoʻohui

haaheoi nā māhele a Rosulip,
ka hana ikaika no ka maʻi o ka ate, me ka hoʻomau mau ʻana o ka hana serum transaminase,
kaumaha hana koʻikoʻi o nā pūlima, me ka hoʻomaʻemaʻe mea hanaa i 30 ml mau minuke,
myopathya i predisposition i nā hua'ōlelo myotoxic,
hānai Cyclosporine,
wahine i ka wā hāpai a me ka lactation,
makahiki he 18 mau makahiki,
i ka pili ana me nā ʻike i ka hoʻomākaukau lactosecontraindication ʻo ia molololo, neleʻaʻano - lactaseskomo me glucose galactose glucose.

Hoʻohana ʻia kēia lāʻau lapaʻau me ka mālama aka inā he pilikia o ka hoʻolālā. myopathieskekahi rhabdomyolysis, pilikia kūloheloheka mōʻaukala o ka maʻi ate, me sepsis, haehae maʻi, hypothyroidism.

Eia kekahi, me ka mālama aka, ʻo kā Rosulip therapy e mālama ʻia i nā poʻe maʻi e hoʻopau nui waiʻonama mua o 65 mau makahiki, he lāhui ʻAmelika e noi ana nā huaʻaika loaʻa ʻana o ka kukuna plasma nui o ka rosuvastatin, ka nui o ka hōʻeha ʻana a i ʻole kaʻeha.

Ke keu

Ke lawe ʻia i ka nui o nā koina o ka rosuvastatin, pono e mālama ʻia ka hōʻailona hōʻailona, no ka mea hoʻololi pū ʻia ʻaʻole i kēia mau lā, akā ke kūleʻa hemodialysis makemake ʻole. Eia kekahi, pono e hoʻokō i nā hana e manaʻo nei e mālama i nā hana koʻikoʻi, ua paipai ʻia e kāohi i nā pae o serum CPK a me nā hana ate.

Hoʻohui

Me ka Cyclosporin AUCrosuvastatinhoʻonui i ka awelika ʻehiku ma mua o ka mau limahana olakino, no ka hoʻohui, ʻo ke kaila o ka plasma o rosuvastatin e piʻi i nā manawa he ʻumikūmākahi, a ʻaʻole loli ʻo Cyclosporine.
Me ka antagonis huaora K( Warfarin) i ka hoʻomaka ʻana o ka lāʻau Rosulip a i ʻole me ka piʻi o ka nui o ka lāʻau lapaʻau, hoʻonui paha ʻo PV a me MHO. ʻO ka hoʻoneʻe ʻana o Rosulip a i ʻole ka hōʻemi ʻana i ka paneʻana hiki ke alakaʻi i ka hōʻemi o ka MHO, no laila pono pono ka mana o ka MHO.
ʻO ka hui pū ʻana o rosuvastatin me Gemfibrozila lehelehe-lipʻo ke ala hiki ke alakaʻi i kahi kānalua o ka hoʻokaʻawa plasma kiʻekiʻe a me AUC o ka rosuvastatin.
Me ka Ezetimibehiki ke launa pūkaʻi me ka hoʻomohala ʻana o nā hopena ʻaoʻao.
Me ka nā mea pale o protease - hiki ke hoʻonui nui ʻia i ka ʻike ʻana i ka rosuvastatin.
Me nā antacids, kahi emi o ke kaila o ka plasma o rosuvastatin e like me ka nui o 50% e nānā ana.
Me ka Erythromycin- ke emi ʻana o AUC o rosuvastatin e ka 20% a me Cmax e 30%, kāhea paha ma muli o ka ulu ʻana o ka ʻōpū i lalo o ka hana a ka erythromycin.
Me ka nā mea hoʻohālikelike waha a i ka manawa Hāʻawi hoʻokolohua hormone ʻO AUC o ka ethinyl estradiol (ma o 26%) a me ka norgestrel (e 34%) hoʻonui.
ʻO ka hoʻohana pū ʻana o nā lāʻau lapaʻau e loaʻa ana i ka rosuvastatin me Itraconazole(kahi paʻa o ka isoenzyme CYP3A4) e alakaʻi i ka piʻi ʻana o ka AUC o rosuvastatin ma kahi o 28%, he ʻano maʻi ia.

Nā kikowaena Rosulip

Nā māku e like me nā hōʻike

ʻO ke kumukūʻai mai 54 mau rubles. ʻOi aku ka maʻalahi o ka analogue ma ka 384 rubles

Nā māku e like me nā hōʻike

Kumukūʻai mai 324 mau rubles. ʻO ka analogi ka mea kūʻai loa ma ka 114 mau rubles

Nā māku e like me nā hōʻike

ʻO ke kumukūʻai mai 345 rubles. ʻO ka analogue he 93 rubles maʻalahi

Nā māku e like me nā hōʻike

ʻO ke kumukūʻai mai 369 rubles. ʻOi like ka analogue ma o 69 mau rubles

Nā māku e like me nā hōʻike

ʻO ke kumukūʻai mai 418 mau rubles. ʻOi like ka analogi ma o 20 mau rubles

Nā māku e like me nā hōʻike

ʻO ke kumukūʻai mai 660 rubles. Ua ʻoi aku ka uku o ka analogue ma ka 222 mau rubles

Nā māku e like me nā hōʻike

ʻO ke kumu kūʻai mai 737 mau rubles. Ua ʻoi aku ka uku o ka analogue ma ka 299 mau rubles

Nā māku e like me nā hōʻike

ʻO ke kumukūʻai mai 865 rubles. Ua ʻoi aku ka uku o ka analogue ma ka 427 mau rubles

Ka hana lāʻau lapaʻau

ʻO Rosuvastatin kahi mea koho koho kūwaho a hoʻokūkū hoʻi o ka hoʻoneʻe ʻana o HMG-CoA, kahi enzyme e hōʻiliʻili nei i ka huli ʻana o 3-hydroxy-3-methylglutaryl-coenzyme A i ka mevalonate, kahi mea i mua o ka cholesterol (Xc). Hoʻonui ka Rosuvastatin i ka nui o nā receptors LDL ma ka ʻaoʻao o nā mea momona, e hoʻonui ai i ke kao a me ka catabolism o LDL, a pale pū hoʻi i ka synthesis o VLDL i ka puʻuwai. ʻO ka hopena, ua hoʻemi ʻia ka nui o ka nui o VLDL a me LDL.

Hoʻemi i ka hoʻonui nui ʻana o ka cholesterol lipoprotein haʻahaʻa haʻahaʻa (HDL-C), ka nui o ka kolamu a me ka triglycerides, a ke hoʻonui nei hoʻi i ka piʻi ʻana o ka momona lipoprotein kiʻekiʻe (HDL-C). Eia kekahi, hoʻohaʻahaʻa ka rosuvastatin i ka hoʻololi ʻana o ka apolipoprotein B (ApoB), non-HDL cholesterol (Xc-non-HDL cholesterol), nā haʻahaʻa lipoprotein haʻahaʻa haʻahaʻa (Chs-VLDL), a me ka haʻahaʻa haʻahaʻa lipoprotein triglycerides (TG-VLDL) a hoʻonui i ka ʻike o ka apolipoprotein I (Apipote) )

Hoʻololi ʻo Rosuvastatin i ka pālākiō o Xs-LDL / Xs-HDL, paukū kolesterol / Xs-HDL, Xs-non-HDL / Xs-HDL a me ApoV / ApoA-I.

ʻO ka hopena therapeutic o ka lāʻau lapaʻau e hōʻike i loko o hoʻokahi pule ma hope o ka hoʻomaka ʻana o ka mālama ʻana. I nā 2 mau pule o ka lapaʻau, hiki i ka hana kūpono ke pae o 90% o ka nui. Loaʻa ka hopena therapeutic kiʻekiʻe loa e ka hopena o ka wiki 4 ma ka mālama ʻia a mālama ʻia me ka hoʻohana maʻamau.

ʻAʻole i ʻike ʻia ka palekana a me ka hana o ka rosuvastatin ma ka lahui pediatric. No kēia māhele o nā mea maʻi, ua palena wale ʻia ka ʻike o ka hoʻohana ʻana i ka lāʻau liʻiliʻi i ka helu liʻiliʻi o nā mea maʻi (ʻo 8 mau makahiki a keu paha) me ka hypercholesterolemia hoʻoilina homozygous.

Lapaʻau lāʻau

C_max Loaʻa ka plasma rosuvastatin ma kahi o 5 mau hola ma hope o ka nānā ʻana. ʻO ka bioavailability pololei o ka lāʻau e pili ana i 20%.

Hoʻopili ʻia ka Rosuvastatin e ka pepi, kahi e kū ai ka synthesis nui o ka cholesterol a me ka ʻāʻī o LDL-C. V_{e d} hiki i ka rosuvastatin i ka 134 lita.

Ma kahi o 90% o rosuvastatin e hoʻopili ai i nā protein plasma, ʻoi ka albumin.

Rosuvastatin ka lalo ʻana o ka hoʻokūkī ʻai liʻiliʻi (ma kahi o 10%) i loko o ka ate. He ia kahi-diea substrate no ka isoenzymes o ka ʻōnaehana cytochrome P450. ʻO ka isoenzyme nui i komo i ka hana o ka rosuvastatin ʻo CYP2C9. ʻO Isoenzymes CYP2C19, CYP3A4 a me CYP2D6 i emi iki i ka hana metabolism.

ʻO nā metabolites nui i ʻike ʻia o ka rosuvastatin ʻo nā metabolites N-desmethyl a me ka lactone. Ma kahi o N-desmethyl ma kahi o 50% emi iki ma mua o ka rosuvastatin, nā metabolite lactone o ka pharmacologically hana ʻole. ʻOi aku ma mua o ka 90% o nā lāʻau lapaʻau i ka pale ʻana i ka hoʻoliʻiliʻi HMG-CoA i hāʻawi ʻia e rosuvastatin, ʻo ke koena ka metabolites.

Ma kahi o 90% o kahi o ka rosuvastatin e excreted i hoʻololi ʻia e loko o nā ʻōpū.

Ma kahi o 5% o ka loaʻa i ka excreted i hoʻololi ʻia e nā keiki. T_1/2 ka lāʻau lapaʻau mai ke kahe koko koko ma kahi o 19 mau hola a ʻaʻole e loli me ka hoʻonui ʻana o ka nui o ka lāʻau lapaʻau. ʻO ka wehe o ka plasma o ka rosuvastatin i ka awelika o 50 l / h (coefficient of variation - 21.7%).

E like me nā HMG-CoA reductase inhibitors, ʻo ka mea lawe kīlea o ka membrane o ka cholesterol i pili i ka uppake hepatic o rosuvastatin, he mea nui ka hana i ka hepatic elimination o rosuvastatin.

Hoʻonui ka systemic bioavailability o ka rosuvastatin i ka pānaʻi ʻana i ka nui. Ke hoʻohana nei i ka lāʻau lapaʻau i kekahi mau manawa i ka lā, ʻaʻole loli ka nui o ka pharmacokinetic.

ʻO ka Pharmacokinetics i nā hui hoʻomanawanui kūikawā

ʻAʻole pili ka pōpilikia a me kou makahiki i nā hopena koʻikoʻi o ka maʻi ma ka pharmacokinetics o rosuvastatin.

Ua hōʻike ʻia nā haʻawina ʻo Pharmacokinetic i kahi hoʻonui o twofold i ke median AUC a me C_max ʻO ka rosuvastatin plasma i nā mea maʻi o ka lāhui Mongoloid (Kepani, Kina, Pilipino, Vietnamese a me Koreans) i hoʻohālikelike ʻia me nā ʻelele o ko ka iwi Caucasian, i nā mea maʻi maʻi India, he hoʻonui nui ka ʻAUC median a me C i hōʻike ʻia._max 1.3 mau manawa. ʻAʻole i hōʻike ʻia ka loiloi i nāʻokoʻa ʻē aʻe o ka pharmacokinetics i waena o nā ʻelele o ka lāhui Caucasian a me nā ʻelele o ka lāhui Negroid.

I nā mea maʻi me ka hina ʻole a me ka hoʻololi ʻole, a i ʻole ka loli o ka plasma o ka rosuvastatin a i ʻole N-desmethyl e loli nui. I nā mea maʻi me ka maʻi renal koʻikoʻi (CC ma lalo o 30 ml / min), ʻo ke kaila o ka rosuvastatin i loko o ke koko he 3 mau manawa ke kiʻekiʻe, a ʻo ka neʻe o N-desmethyl he 9 mau manawa kiʻekiʻe ma mua o nā mea hana olakino olakino. ʻO ka plasma o ka rosuvastatin i loko o nā mea maʻi ma ka hemodialysis ma kahi o 50% kiʻekiʻe ma mua o nā mea hana olakino.

ʻO nā mea maʻi me nā ʻāpana like ʻole o ka palekaleka i ʻole i hoʻonui i ka T_1/2 rosuvastatin (nā mea maʻi me ka helu o 7 a i lalo paha ma ke kāʻei keiki-Pugh). 2 nā mea maʻi me nā helu 8 a 9 ma ke kāla ʻo Child-Pugh i hōʻike i ka hoʻonui i T_1/2ka liʻiliʻi 2 manawa. ʻAʻoheʻike i ka hoʻohana ʻana o rosuvastatin i nā maʻi me ka māka i ʻoi aku ka 9 ma luna o ke kākuhi ʻo Child-Pugh.

- ʻO ka hypercholesterolemia maʻamau (type IIa e like me Fredrickson) a i ʻole like me ka hypercholesterolemia i hui ʻia (type IIb ma muli o Fredrickson) i mea hoʻohui i nā meaʻai, i ka wā e ʻai ai nā meaʻai a me nā ʻano hana ʻole nā lāʻau lapaʻau (ʻoi aku ka hoʻomaʻamaʻa, ua hōʻemi ke kaumaha) ʻaʻole lawa.

- hypercholesterolemia hoʻoilina homozygous ma ke ʻano he meaʻaiʻai a me nā ʻano hana ʻē aʻe e kuhikuhi ana i ka hoʻohaʻahaʻa ʻana i nā lipid kūloko i ke koko (no ka laʻana, ʻo LDL apheresis), a me nā mea kūpono ʻole ka hopena o kēia mau ala.

- hypertriglyceridemia (ʻano IV ma muli o Fredrickson) i mea hoʻohui i ka meaʻai,

- e hoʻolōʻihi i ka holomua o ka atherosclerosis ma keʻano he mea hoʻohui i ka meaʻai i nā mea maʻi, ʻo ia nā mea e hōʻike ʻia ana i ka lāʻau e hōʻemi i ke kiʻekiʻe o ka Chs a me Chs-LDL,

- kaohi ʻana o nā hōʻeha cardiovascular nui (stroke, myocardial infarction, arterial revascularization) i nā poʻe maʻi me nā hōʻailona ʻole o ka maʻi o ka artery coronary, akā me ka piʻi o ka ulu ʻana (ma mua o 50 mau makahiki no nā kāne a ʻoi aku ʻo 60 mau makahiki no ka poʻe wahine, hoʻonui nui i ka protein C-reactive (≥2 mg / L) i mua o ka liʻiliʻi o kekahi o nā mea e pili ana i ke kinikini, e like me ka arterial hypertension, haʻahaʻa haʻahaʻa o HDL-C, ka ulaula, kaʻikepili ʻohana ma ka hoʻomaka ʻana o ka maʻi naʻau coronary).

Ka hoʻoponopono ʻia ʻana

Lawe ʻia ka lāʻau lapaʻau. Pono e luku ʻia ka papa ʻaina, holoi ʻia me ka wai, me ka ʻole o ka ʻāʻī ʻole ʻole. Hiki ke lawe ʻia ka Rosulip ® i kēlā me kēia manawa o ka lā, ʻaʻohe mea e kau ai i ka meaʻai.

Ma mua o ka hoʻomaka ʻana i ka mālama ʻana me Rosulip ®, pono ke kuhikuhi ʻia ka mea maʻi i kahi meaʻai maʻamau me ka haʻahaʻa haʻahaʻa haʻahaʻa. Pono ka mea maʻi ma muli o kahi papaʻai i ka papa o ka ʻoihana. Pono ke koho pono o ka lāʻau lapaʻau ka ʻokoʻa ma ke ʻano o ka hōʻike ʻana a me ka pane ʻana i ka therapeutic i ka mālama ʻana, me ka noʻonoʻo ʻana i nā loiloi o kēia manawa i nā pae lipid kiko.

ʻO ka hopena hoʻomaka ʻia o Rosulip ® no nā mea maʻi e hoʻomaka nei e lawe i ka lāʻau lapaʻau, ai ʻole no nā mea maʻi i hoʻoneʻe ʻia mai nā HMG-CoA reductase inhibitors, ʻo 5 a 10 mg 1 mau lā / lā. Ke koho ʻana i kahi pualikoa mua, pono kekahi e alakaʻi e ka maʻi kolamu a ka mea maʻi a mālama i ka pilikia o ke kūkulu ʻana i nā ʻōwili cardiovascular, a he mea pono no hoʻi e loiloi i ka hopena kūpono e pili ana i nā hopena ʻaoʻao. Inā pono, ma hope o 4 mau hebedoma e hoʻonui ʻia ka hopena.

Ma hope o ka noi ʻana i kahi kaʻe o ka nui ma mua o ka wai i hoʻomaka ʻia no nā hebedoma 4, hiki ke hoʻonui ʻia ma hope o 40 mg wale nō i loko o nā mea maʻi me ka hypercholesterolemia koʻikoʻi a me kahi pilikia nui o nā hoʻopiʻi cardiovascular (ʻoi loa i nā mea maʻi me ka hypercholesterolemia familial) ʻaʻole i hoʻokō i ka makemake ka hopena o ka lāʻau i ka wā i hoʻohana ʻia ma kahi kinona o 20 mg, a ma lalo o ka nānā ʻana o kahi loea.ʻAno ke kiaʻi ʻana i ka poʻe maʻi e loaʻa i ka lāʻau lapaʻau ma loko o kahi mīkala o 40 mg.

No ka ka mālama ʻana i nā mea maʻi ma luna o 65 ʻO ka paena hoʻomaka hoʻomaka ʻia he 5 mg. ʻAʻohe pono no nā loli ʻē aʻe e pili ana i nā makahiki o nā maʻi.

ʻO nā mea maʻi me ka hina ʻole a me ke kaulike ʻaʻole koi ʻia ka hoʻoponopono ʻana. ʻO nā mea maʻi me ka hāmeʻa maʻi papalō ʻokoʻa (CC ma mua o 60 ml / min) ke kuhikuhiia i kahi inau mua o 5 mg. ʻO kahi dosis o 40 mg ua contraindicated ma nā maʻi me maʻi hoʻōla i ʻole. ^ E Ha yM. I pilikia kaumaha ʻole Rosulip ® ua contraindicated ma kekahi ʻōmole.

I ka helu ʻana i ka lāʻau lapaʻau ma loko o nā wai hoʻomalu o 10 mg a me 20 mg, ʻo ka pona i hoʻomaka ʻia no nā poʻe maʻi o ka lāhui Mongoloid he 5 mg. Hoʻohana ʻia ka hoʻohana ʻana i ka lāʻau lapaʻau ma loko o kahi hapa o 40 mg i nā maʻi maʻi o ka lāhui Mongoloid.

I ka helu ʻana i ka lāʻau lapaʻau ma nā waiʻauʻau o 10 mg a me 20 mg, ʻo ka pona i hoʻomaka ʻia no nā poʻe maʻi predisposed i ka myopathy ʻo 5 mg. ʻO ka hana o ka lāʻau lapaʻau ma kahi maʻa o 40 mg ua contraindicated i ka poʻe maʻi me nā mea e hōʻike ana i kahi predisposition i ka hoʻomohala ʻana i ka myopathy.

Ma hope o he 2 mau hebedoma o ka lapaʻau a me / a me ke kiʻi ʻana o ka nui o ka hopena o Rosulip ®, ka nānā ʻana o ka lipid metabolism e pono, inā pono, pono ʻia ka hoʻoponopono ʻana.

Loaʻa ka hopena

I ka wā o ka mālama ʻana me ka rosuvastatin, ua hoʻomākoea ʻia ka hopena me ke kūlohelohe a me ka hopena o ke ʻano hemo. E like me nā HMG-CoA reductase inhibitors, ʻo ka nui o nā hopena ʻalike e pili ana me ka lāʻau rosuvastatin e hilinaʻi nei i ka pualikoa.

Ka helu ʻana i nā hana ʻino e like me ke alapine ʻana i ka ulu ʻana: pinepine (mai> 1/100 a 1/1000 a 1/10 000 i

ʻŌpū a me ka lactation

Rosulip ® ua contraindicated ma ka hāpai ʻana a me ka lactation (umauma maʻi). Ke hoʻoholo nei i ka wā hapai i ka wā o ka hōʻola, pono e hoʻopau koke i ka hoʻohana ʻana i ka lāʻau.

ʻO nā wahine o nā makahiki hānau pono e hoʻohana i nā ʻoihana kūpono o ka ʻohu.

No ka mea he mea nui ka kolamu a me kāna mau huahana biosynthesis no ka hoʻoulu ʻana i ka maʻi fetal, hiki i ka nui o ke kūpū o ka pale ʻana i ka hoʻemi ʻana o HMG-CoA ma mua o ka hoʻohana pono ʻana i ka lāʻau.

ʻAʻohe ʻikepili i ka hāʻawi ʻana o ka rosuvastatin me ka waiū umauma, no laila inā ʻoe e hoʻohana i ka lāʻau i ka wā o ka lactation, pono ke hoʻokuʻu ʻia ka umauma.

Hoʻohana no ka hana lawelawe lēwa

ʻO ka lāʻau lapaʻau ma ke ʻano o nā papa o 10 a me 20 mg ke hoʻohālikelike i nā maʻi o ke ake i ka hana ikaika, me ka hoʻomau i ka hoʻonui ʻana i ka hana serum transaminase a me ka hoʻonui ʻana i ka hana serum transaminase (ʻoi aku ma mua o 3 mau manawa i hoʻohālikelike ʻia me VGN). Me ka mālama aka, pono e kuhikuhi ʻia ʻo Rosulip ® i ka maʻa o 10 a me 20 mg no ka mōʻaukala o nā maʻi o nā ate.

ʻO ka lāʻau lapaʻau ma ke ʻano o nā papa he 40 mg e hoʻohālikelike i nā maʻi o ka puʻuwai ma ka hana ikaika, me ka hoʻomau i ka hoʻonui ʻana i ka hana serum o nā transaminases a me ka hoʻonui ʻana i ka hana o nā transaminases ma ka serum o ke koko (ʻoi aku ma mua o 3 mau manawa hoʻohālikelike ʻia me VGN), ka ʻike no ka hoʻohana ʻana i ka lāʻau lapaʻau i nā mea maʻi me ka ʻoi aʻe ʻoi aku ka 9 ma luna o ka Palau ke keiki-Pugh i nalowale. Me ka mālama aka, pono e kuhikuhi ʻo Rozulip ® i kahi pānaʻi o 40 mg no ka mōʻaukala o nā maʻi o nā ate.

Hoʻohana no ka hana renal impaired

ʻO ka lāʻau lapaʻau i ke ʻano o nā papa o 10 a 20 mg ua contraindicated ma ka hoʻonāukiuki ʻana i ka maʻi haneli (CC ma mua o 30 ml / min). Me ka mālama aka, pono e kuhikuhi ka lāʻau i nā mika i ke 10 a me 20 mg no ka maikaʻi ʻole o ka renal.

ʻO ka lāʻau lapaʻau i ke ʻano o nā papa o 40 mg ua contraindicated i ka hana renal moderate (CC ma mua o 60 ml / min). Me ka mālama aka, pono e hoʻohana ʻia ka lāʻau lapaʻau ma ke ʻano o nā papa he 40 mg i nā maʻi me nā maʻi renal light (CC ma mua o 60 ml / min).

Nā ʻōlelo kikoʻī

Ke hoʻohana nei i ka lāʻau lapaʻau Rosulip ® i kahi lāʻau o 40 mg, ʻoi ʻia ke nānā i nā māka hana o nā hana.

Ke hoʻohana nei i ka lāʻau lapaʻau Rosulip ® i nā āpau āpau, ʻoi aku ka nui o ka 20 mg, ka hoʻomohala ʻana i ka myalgia, myopathy a, i nā hihia loaʻa ʻole, ua hōʻike ʻia ka rhabdomyolysis.

ʻAʻole pono e hoʻokau i ka hana ʻo CPK ma hope o ka hoʻoikaika kino loa a i ʻole i ke alo ʻia i nā kumu ʻē aʻe paha no ka hoʻonui ʻana i ka hana CPK, hiki iā ia ke kuhikuhi i ka wehewehe pololei ʻana i nā hopena. Inā hoʻonui ʻia ka hana mua o CPK (5 mau manawa kiʻekiʻe ma mua o VGN), ma hope o nā lā 5-7, e hana ʻia kahi lua. ʻAʻole ʻoe e hoʻomaka ma kahi hoʻopaʻa inā hōʻoia ka hoʻokolohua i kahi hana nui o KFK (mau manawa 5 ma mua o VGN).

Ma ke kuhikuhi ʻana iā Rosulip ® (a me nā HMG-CoA reductase inhibitors) i nā mea maʻi me nā mea e pili ana i ka rhabdomyolysis, pono pono e noʻonoʻo i ka hoʻohālikelike o nā pōmaikaʻi e hiki mai ana a me nā hopena kūpono a mālama i ka nānā ʻana i nā mea lapaʻau.

Hoʻomaopopo ʻia ka mea maʻi i ka pono e hōʻike koke i ke kauka e pili ana i nā hihia o ka hoʻomaka koke ʻana o ka ʻeha o ka naʻau, nā ʻōpū palupalu a i ʻole ka hoʻopili ʻana, ka pūliki me ka maʻi mū a me ke kuni. I kēlā mau mea maʻi, pono e hoʻoholo ʻia ka hana CPK. Pono e hoʻokuʻu ʻia ka therapy inā hoʻonui ʻia ka hana o ka CPK (ʻoi aku ma mua o 5 mau manawa e hoʻohālikelike ʻia me VGN) a inā i ʻōlelo ʻia nā hōʻailona ʻalā a hana hou ʻia nā lā a pau (ʻoiai inā ka hana o CPK he 5 mau manawa i hoʻohālikelike ʻia me VGN). Inā nalowale nā hōʻailona, a hoʻi hou ka hana ʻo CPK, pono e noʻonoʻo e koho hou iā Rosulip a i ʻole ko HMG-CoA reductase inhibitors i nā haʻahaʻa haʻahaʻa me ka kiaʻi pono ʻana o ka mea maʻi. ʻO ke kāohi pono ʻana i nā hana CPK i ka haʻalele ʻana o nā hōʻailona kūpono ʻole. ʻAʻohe hōʻailona i hoʻonui ʻia i ka hopena o nā mea ponana i ka ʻili o ke kākala i ka wā e hoʻohana ana iā Rosulip ® ma ke ʻano o ka hui hoʻohui ʻana. I ka hoʻonui ʻia o ka ulu ʻana o myositis a me myopathy i hōʻike ʻia i nā mea maʻi i lawe i nā poʻe hoʻoliʻi HMG-CoA reductase e hui pū me nā derivatives acid fibroic (me nā gemfibrozil), cyclosporine, acid acid nikotinic i nā lipid-hoʻohaʻahaʻa i nā dosis (ʻoi aku ma mua o ka 1 g / lā), nā lāʻau lapaʻau azole antifungal, me ka pale aku. Nā proteases a me nā antibiotics mai ka hui macrolide. Hoʻonui ka Gemfibrozil i ka nui o ka myopathy i ka wā i hāʻawi ʻia me ka poʻe HMG-CoA reductase inhibitors. No laila, ʻaʻole i ʻōlelo ʻia ʻo ka hoʻomohala pinepine ʻana i ka lāʻau Rosulip ® a me gemfibrozil. Pono ka pālaha o ka pōmaikaʻi i hāpai ʻia a me nā mea e hiki ai ke mālama ʻia me ka hoʻohana pū ʻana o ka lāʻau Rosulip ® a me nā fibrates a i ʻole ka nikotinic acid i nā lipid-hoʻohaʻahaʻa i ka wai (ʻoi aku ma mua o 1 g / lā).

2-4 mau pule ma hope o ka hoʻomaka ʻana o ka lāʻau lapaʻau a me / a me ka hoʻonui ʻana o ka maʻa o Rosulip ®, ka nānā ʻana o ka lipid metabolism e pono (pono ʻia ka hoʻoponopono ʻana inā pono).

Hoʻomaopopo ʻia e koho i ka hana o nā transaminases ma mua o ka hoʻomaka ʻana o ka lāʻau a me 3 mau mahina ma hope o ka hoʻomaka ʻana o ka hoʻomaʻamaʻa. Pono e hōʻemi ʻia ka lāʻau lapaʻau Rosulip ® a i ʻole ke hōʻemi ʻia i ka hopena inā he hana nā transaminases i loko o ke koko serum he 3 mau manawa ma mua o VGN.

I ka poʻe maʻi me ka hypercholesterolemia ma muli o ka hypothyroidism a iʻole nephrotic syndrome, e pono e lawe i ka lāʻau o nā maʻi nui ma mua o ka hoʻomaka ʻana o ka mālama ʻana me Rosulip ®.

Loaʻa ʻia ka maʻi maʻi a me ka ʻikepili e pili ana i ka hoʻohana ʻana i ka lāʻau lapaʻau i nā mea maʻi me ka hana aho i pili ʻia i ka ʻoi aku ma mua o 9 mau keiki-Pugh i loaʻa ʻole.

Ua hōʻike pinepine ʻia nā maʻi ʻino interstitial i loko o nā poʻe maʻi i mālama ʻia me kekahi mau lāʻau statin. ʻO ka maʻamau, ua nānā ʻia kēia mau hihia me ka lōʻihi o nā statin therapy. Hōʻike ʻia ka maʻi ʻōlohelohe interstitial e ka pōkole o ka hanu, ka umukū hū ʻole a me ka nui o ke ʻano nui (ka luhi, ke kaupaona ʻana a me ke alualu). Inā kānalua ka maʻi lemela interstitial, pono e hoʻokuʻu ʻia ka lāʻau statin.

Hōʻike nā hualoaʻa o nā haʻawina pharmacokinetic i nā poʻe maʻi o ka lāhui Mongoloid, ʻoi aku ka kiʻekiʻe o ka bioavailability o rosuvastatin ma mua o nā mea i hoʻohālikelike ʻia o ka lāhui Caucasoid.

ʻAʻole pono ke lawe ʻia ka Rosulip ® i nā mea maʻi me ka intolerance lactose, ka nele o ka lactase a me ka malabsorption glucose-galactose. ka hopena lāʻau i ka lactose.

Hoʻohana ʻo Pediatric

I ka kūpono a me ka palekana o ka lāʻau lapaʻau i loko na keiki a me na opio malalo o na makahiki 18 ʻaʻole i hoʻonohonoho ʻia. Loaʻa ka ʻike no ka hoʻohana ʻana i ka lāʻau lapaʻau ma ka hana pediatric i kahi helu liʻiliʻi o nā keiki (mai 8 mau makahiki ʻoi aku a ʻoi aku) me ka ʻohana homozygous hypercholesterolemia. I kēia manawa, ʻaʻole ʻōlelo ʻia ʻo Rosulip ® no ka hoʻohana ʻana i nā keiki.

Hoʻokomo i ka hiki ke lawe i nā kaʻa a kāohi i nā mīkini

E akahele ka poʻe maʻi i ka wā e holo a hana paha, koi ai i ka piʻi ʻana o ka nānā a me ka wikiwiki o ka hopena psychomotor, no ka mea hiki ke hele mai ka maʻi lahilahi i ka wā o ka therapy.

Hoʻohui nūhou

Lualope: me ka hana like o rosuvastatin a me ka cyclosporine, ʻo AUC o ka rosuvastatin ma ka nui he 7 mau kiʻekiʻe ma mua o ka mea i ʻike ʻia i nā mea hana olakino. Ke alakaʻi nei ka manawa like i ka hoʻonui ʻana i ka paʻa ʻana i ka rosuvastatin i loko o ke koko koko e 11 mau manawa, ʻaʻole i loli ka plasma i ka cyclosporine.

Nā Huaʻōlelo K ka hoʻomaka ʻana o ka lāʻau rosuvastatin a i ʻole ka hoʻonui ʻana i ka maʻa i nā mea maʻi e loaʻa ana i ka like me ka vitamin K antagonist (e like me, warfarin) hiki ke piʻi i ka manawa o ka manawa prothrombin a me MHO. ʻO ka hoʻoneʻe ʻana o rosuvastatin a i ʻole ka hōʻemi ʻana i kona makeʻana hiki ke piʻi i kahi kaila o ka MHO. I kēlā mau kūlana, ua kauoha ʻia ka mana o ka MHO.

Nā lāʻau momona Gemfibrozil a me nā lipid. ka hui like ʻana o rosuvastatin a me gemfibrozil e alakaʻi i kahi hoʻonui 2-pae i C_max i loko o nā koko koko a me AUC o rosuvastatin. Hiki ke launa pū me ka Pharmacodynamic. ʻO nā Gemfibrozil, nā mea ʻē aʻe, a me ka waika nikotinic i loko o nā lipid-hoʻohaʻahaʻa i ka palena (ʻoi aku ma mua o 1 g / lā) i hoʻonui ʻia i ka hopena o ka myopathy i ka wā i hoʻohana pū ʻia me nā HMG-CoA reductase inhibitors, hiki nō paha no ka mea hiki ke hoʻopiʻi ʻia i kuʻu manaʻo a i hoʻohana ʻia monotherapy. ʻOiai e lawe ana i ka lāʻau lapaʻau me gemfibrozil, fibrates, ka waikū nikotinic ma nā lipid-e hoʻohaʻahaʻa i ka wai (ʻoi aku ka nui o ka 1 g / lā), ua ʻōlelo ʻia kahi hopena o 5 mg no nā maʻi. ʻO ka maʻi me ka rosuvastatin ma kahi kikoʻī o 40 mg ua contraindicated me ka hoʻohana mua ʻana o nā fibrates.

Ezetimibe: ka manawa like ʻole o ka hoʻohana ʻana i ka lāʻau Rosulip ® a me ezetimibe i hele ʻole ʻia e kahi loli ma AUC a me C_max nā lāʻau ʻelua. Eia nō naʻe, ʻaʻole hiki ke hoʻoholo ʻia i ka launa ʻo pharmacodynamic me ka hoʻolālā ʻana o nā hopena ʻaoʻao ma waena o ka rosuvastatin a me ka ezetimibe.

ʻO ka pale ʻana i ka proteamine HIV: ʻoiai ʻaʻole maopopo ka ʻike maoli o ka launa, ʻo ka hoʻokele ʻana o ka inhibitor o ka protease HIV i hiki ke alakaʻi i kahi nui nui o ka hoʻolaha ʻana o ka rosuvastatin. Ke noiʻi nei ʻo pharmacokinetic o ka hoʻohana like ʻana o 20 mg o rosuvastatin me ka hoʻomākaukau hui pū ʻana i loaʻa i ʻelua mau protease inhibitor (400 mg o lopinavir / 100 mg o ritonavir) i nā mea hana olakino makemake e alakaʻi i kahi e pili ana i ka nui o ʻelua mau pākani a elima-lipine i ka AUC._(0-24) a C_max rosuvastatin, kekahi. No laila, ʻaʻole i ʻōlelo ʻia ka hoʻomohala pinepine ʻana i ka rosuvastatin a me nā inhibitor ʻo protease i ka mālama ʻana i nā maʻi maʻi HIV.

ʻĀpono: ka manawa like o ka rosuvastatin a me nā suspacant antacid e loaʻa ana i ka alumini a me ka hoʻōkena magnesium hydroxide e alakaʻi i ka emi ʻana o ka plasma o ka rosuvastatin ma kahi o 50%. Hōʻike ʻia kēia hopena inā ke hoʻohana ʻia ka hoʻokuʻu ʻana i nā antacids i mau hola 2 ma hope o ka lawe ʻana i ka rosuvastatin. ʻAʻole i aʻo ʻia ka maʻi koʻikoʻi o kēia pilina.

Erythromycin: ka manawa like me ka rosuvastatin a me ka erythromycin e alakaʻi i kahi emi ʻana o AUC o rosuvastatin e 20% a me C_maxrosuvastatin e 30%, ʻoiai paha ma muli o ka nui o ka motility intestinal i manaʻo ʻia ma ke lawe ʻana i ka erythromycin.

Oral contraceptives / hormon replacement therapy (HRT):ka manawa like o ka rosuvastatin a me nā kūmole waha e hoʻonui i ka AUC o ka ethinyl estradiol a me ka AUC o norgestrel e 26% a 34%, kekahi. Pono e hoʻonui ʻia i ka neʻe ʻana o ka plasma i ka wā e koho ai i ka nui o nā maʻi kūlohelohe o ka waha me Rosulip. Ua huikau ka ʻikepili Pharmacokinetic i ka hoʻohana pinepine ʻana o Rosulip a me HRT, no laila, ʻaʻole hiki ke haʻalele ʻia kahi hopena like me ka hoʻohana ʻana i kēia hui ʻana. Akā, ua hoʻohana nui ʻia kēia hui i ka wā o nā hoʻokolohua lapaʻau a ua hoʻomanawanui maikaʻi ʻia e nā mea maʻi.

ʻO nā lāʻau ʻē aʻe: ʻaʻohe ʻano hui like ʻole o ka rosuvastatin me ka digoxin.

Isoenzymes o ka cytochrome P450: in vivo and in vitro Studies has hōʻike that rosuvastatin is not a inhibitor nor or inducer of isoenzymes of the cytochrome P450 system. Eia kekahi, ʻo ka rosuvastatin kahi palupalu palupalu no kēia isoenzymes. ʻAʻole i loaʻa ke ʻano o ka maʻi koʻikoʻi ma waena o rosuvastatin a me fluconazole (kahi mea paʻa o ka isoenzymes CYP2C9 a me CYP3A4) a me ketoconazole (kahi mea paʻa o ka isoenzymes CYP2A6 a me CYP3A4). Hoʻohui nui ʻia ka hoʻohana ʻana o rosuvastatin a me ka itraconazole (kahi paʻa o ka isoenzyme CYP3A4) e hoʻonui i ka AUC o rosuvastatin e ka 28% (kūmole i hana ʻole ʻia). No laila, ʻaʻole i manaʻo ʻia nā pilina pili me ka ʻōnaehana Pulaa cytochrome P450.

ʻO ka palekana o ka lawe ʻana i ka lāʻau

Eia naʻe ka paʻa a me ka palekana o ka hoʻohana ʻana i kēia lāʻau lapaʻau e nā poʻe lawelawe. ʻAʻohe helu helu helu no ka mālama ʻana o nā keiki ma lalo o 18 makahiki.

No ka poʻe maʻi i ʻoi aku o ka makahiki o 70, ke kuhikuhi ke kauka i ka hoʻohana ʻana i ka lāʻau lapaʻau ma ka palena liʻiliʻi loa.

Hoʻohana wale ʻia ka Rosulip plus me nā lāʻau lapaʻau ʻē aʻe.

ʻO nā mea maʻi me ka hana ʻole ālahele liʻiliʻi e pono ai e hoʻoponopono i ka dosage. I ka hōʻemi kino ʻana i nā maʻi, hiki ke hoʻohana wale i ka lāʻau inā ke hoʻohana ʻole ʻia ka hoʻohana ʻana i nā lāʻau i nā hopena.

Me nā pale liʻiliʻi o ka ate, ʻaʻole pono ke hoʻoponopono ʻia. ʻAʻole ʻōlelo ʻia ʻo Rosulip no nā maʻi e loaʻa ana i nā maʻi hepatic palupalu a i ʻole ka maʻi maʻi, a me nā maʻi maʻi maʻi.

Ke ʻano o ka noi

No ka mea maʻi me ka hana renal éduction maʻalahi (ʻoin ʻo Cl ma mua o 60 ml / min), ua ʻōlelo ʻia ma kahi mua o 5 mg. Hoʻokomo ʻia kahi dosis o 40 mg i loko o nā mea maʻi me ka hana pūnāwai māmā. Ma kahi hōʻeha renal nui, contulicated ʻo Rosulip i kekahi ʻōmole.
Ke koho ʻana i nā pākēneka o 10 a me 20 mg, ʻo ka paipai mua o nā maʻi no ka poʻe maʻi o ka lāhui Asia he 5 mg. Hoʻopili ʻia ka hoʻomalu ʻana o ka lāʻau i ka maʻa o 40 mg no nā maʻi o ka lāhui ʻAiwi.
Ke koho ʻana i nā pawaʻe o 10 a me 20 mg, ʻo ka pona i hoʻomaka ʻia no nā maʻi nā predisposed i ka myopathy ʻo 5 mg. ʻO ka hana o ka lāʻau lapaʻau ma kahi maʻa o 40 mg, ua contraindicated i ka poʻe maʻi me nā mea e hōʻike ana i kahi predisposition i ka hoʻomohala ʻana i ka myopathy.
Ma hope o 2-4 mau hebedoma e pili ana i ka lāʻau a me / a me ka hoʻonui ʻana o ka hopena o Rosulip, pono ka nānā ʻana o ka metabolism lipid, pono a hoʻoponopono ʻia ka lāʻau inā pono.

ʻĀpana Pharmacological

ʻO nā lāʻau hōʻemi i ka kolamu serum a me nā triglycerides. HMG-CoA reductase inhibitors. IX code C10A A07.

ʻO ka hypercholesterolemia mua (type Pa, me ka ʻokoʻa o ka hypercholesterolemia familial heterozygous), a i ʻole ʻili ʻia ka dyslipidemia (type IIb) i ke ʻano o ka ʻai, i ka wā e hiki mai ai ka hopena o kahi kīkeke a i ʻole nā lāʻau lapaʻau like ʻole (e like me ke hoʻomaʻamaʻa ʻana, ʻo ka nui o ke kaumaha) ʻaʻole lawa.

Homozygous familial hypercholesterolemia ma ke ʻano he meaʻaiʻai a me nā ʻano lāʻau hypolipidemic hou (e.g. LDL apheresis), a i ʻole nā kūpono o nā ʻano lapaʻau.

Kākoʻo o ka maʻi Cardiovascular

Hōʻike ʻia ka Rosulip ® e hōʻemi i ka hopena o nā hanana cardiovascular koʻikoʻi i nā poʻe maʻi me ka piʻi nui o ka hoʻomohala ʻana i nā maʻi cardiovascular atherosclerotic, e like me ka ʻike ʻia ʻana o nā mea pili e like me ka makahiki, ka uahi arterial, hōʻemi HDL kolamu, hoʻokiʻekiʻe i C-reactive protein i ka ulaula a i ʻole ka hanana ʻohana i ka ulu ʻana o ka maʻi naʻau coronary.

I mea e lohi ai a hoʻolohi paha i ka hoʻomohala ʻana o ka maʻi i nā maʻi e hōʻike ʻia ana nā lipid-hina haʻahaʻa.

Na keiki a ʻōpio (mai 10 a 17 mau makahiki: mau keikikāne - stage II me ka nui o ka Tanner a ma luna aʻe, nā kaikamahine - ʻo ka liʻiliʻi ma ka makahiki ma hope o ke kāne neʻe.

ʻO ka mālama ʻia ʻana o ka hypercholesterolemia maʻamau (type Pa) a i ʻole ʻae ʻia ka dyslipidemia (type IIb) ma muli o ka hechrolesterolemia ʻohana heterozygous ma ke ʻano o ka meaʻai, i ka wā o ka hopena o ka ʻai ʻana a i ʻole nā ʻano lāʻau lapaʻau ʻē aʻe (e like me ke hoʻomaʻamaʻa, hōʻemi kaumaha) ʻaʻole lawa.

ʻO nā hopena ʻino

ʻO nā hopena ʻinoʻino e nānā ana me Rosulipu ® i ka maʻalahi a me ka transient.

Mai ka pā kūlohelohe : nā hopena maʻi hypersensitivity, me ka angioedema.

Mai ka hoʻonā endocrine: maʻi mellitus maʻiʻi.

Mai ka pūnaehana pili ʻana : headache, dizziness.

Mai ka gastrointestinal tract : constipation, nuala, ʻeha ʻeha, pancreatitis.

Ma ka ʻāpana o ka ʻili a me ka kiko. ʻeha, ʻeha, a me nā ʻūlū.

Mai ka ʻōnaehana musculoskeletal, ka pilina pili a me nā iwi : myalgia myopathy (me loko o kaʻu myositis) a me rhabdomyolysis.

Kūlana nui: ʻaiaiaia.

E like me nā HMG-CoA reductase inhibitors, ʻo ka nui o nā hopena ʻino e hilinaʻi ana.

Hoʻomaʻa i nā aʻala

I ka poʻe maʻi e loaʻa ana iā Rosulip ®, aia kahi mau o ka proteinuria, ka hapa nui o ke kumu tubular (hoʻoholo i ka hoʻohana ʻana i kahi kānana hoʻokolokolo).

Hoʻohui i nā io uaua o ka ʻūlū

Ma ka ʻaoʻao o nā ʻūhā keaka, e like me ka myalgia, myopathy (me loko o ka myositis) a me ka nui o ka rhabdomyolysis me ka loaʻa ʻole o ka renal hina hewa ʻole, i nānā ʻia me nā ʻano like ʻole o Rosulipu ®, me ka nui ʻana o nā dosis> 20 mg. ʻO nā hihia i loaʻa i ka rhabdomyolysis, i pili pū kekahi me ka hiki ʻole o ka renal i hōʻike ʻia, ua hōʻike ʻia me rosuvastatin a me kekahi mau statins.

I ka poʻe maʻi e lawe ana i ka rosuvastatin, ua ʻike ʻia kahi hoʻonui ʻana o ka nui o ka dosis ma ka pae o CPK (CPK); i ka hapanui o nā hihia, palupalu ke hanana, asymptomatic a me kahi pōkole. Inā hoʻokiʻekiʻe ʻia nā pae CK (> 5 mai ka palena palena kiʻekiʻe o ka maʻamau (BMN)), pono e hoʻokaʻawale ʻia ke ʻano lapaʻau.

Pilikia ka pehu

E like me nā HMG-CoA reductase inhibitors, kahi helu liʻiliʻi o nā mea maʻi e lawe ana i ka rosuvastatin i hōʻike i ka maʻi e hilinaʻi nui ana i nā transaminases, ma ka nui o ka maʻi ka palupalu, nā maʻi a asymptomatic a me ka wā lewa.

Ka hopena o nā hōʻailona ʻōkuhi

E like me nā HMG-CoA reductase inhibitors, kahi helu liʻiliʻi o nā mea maʻi e lawe ana i ka rosuvastatin i loaʻa ka maʻi nui-proportional i ke kiʻekiʻe o nā transaminases hepatic a me CPK.

I loko o nā hoʻokolohua lapaʻau lōʻihi lōʻihi, ʻaʻole i hōʻike ʻo Rosulip ® i ka hopena ʻino o ke kūlana o ka mea maʻi;

I nā poʻe maʻi e lawe ana iā Rosulip ®, ʻaʻohe mea o nā uka o ka cortex adrenal.

Hoʻohana ʻo Post-Marketing Application

Ma kahi o ka mea i hōʻike ʻia, i ka manawa o ka noi o ke noi ʻana o Rosulipu ® i kēia mau ʻōhua i hoʻopaʻa ʻia.

Mai ka ʻōnaehana hoʻonāukiuki: polyneuropathy, nalowale hoʻomanaʻo.

Mai ka papa hanu, umauma a me nā ʻōpū mediastinal: huhū, pōkole o ka hanu.

Mai ka pūnaehana hana ʻana: nā ninia

Mai ka pūnaehana hana ʻana: jaundice, hoʻonui ʻia ka maʻi hepatatic transaminases.

Ma ka ʻāpana o ka ʻili a me ka kiko. Hōʻike ʻia ʻo Stevens-Johnson.

Mai ka ʻōnaehana musculoskeletal: immuno-mediated necrotizing myopathy, arthralgia.

Mai nā keiki: hematuria.

ʻO ka maʻi maʻamau a me nā maʻi e pili ana i ke ʻano o ka hoʻohana ʻana i ka lāʻau. ka māla ʻana.

Mai ka ʻōpiopio a me nā kinipona momona: kekekekikia.

Kekahi koko: thrombocytopenia.

I ka hoʻohana ʻana i kekahi statins, ua hōʻike ʻia nā hopena like ʻole:

manaʻo ʻino
nā hana hiamoe, e komo pū me nā loko a me nā pō.
moekolohe,
kekahi mau hihia o ka maʻi interstitial maʻi, ka mea e pili ana i ka hoʻomehana wā lōʻihi,
Nā maʻi tendon, i kekahi manawa paʻakikī e kā lākou pohala.

I ka ulu ʻana o ka rhabdomyolysis, koʻikoʻi a me ka hōʻeha ʻana o ka maʻi hepatic (ʻoi aku ka nui o nā kiʻekiʻe o ka transaminases) ʻoi aku ka nui o ke ʻano o ka nui o 40 mg.

Na keiki he 10 a 17 mau makahiki

Hoʻohālike ka ʻike palekana palekana o Rosulipu ® no nā keiki a me nā pākeke. Eia nō naʻe, no nā keiki a me nā pākeke, nā hana like ʻole no ka hoʻohana ʻana iā Rosulipu ®.

Hoʻohana i ka wā hāpai a me ka lactation

ʻO ka palekana o Rosulipu ® i ka wā hāpai a me ka lactation ʻaʻole i aʻo ʻia.

Rosulip ® ua contraindicated i ka wā hapai a me ka lactation.

Pono nā wahine o nā makahiki hānau i ka wā e lawe ana iā Rosulipu ® i nā mea hoʻohālikelike kūpono.

No ka mea he mea nui ka huahana kolesterol a me nā huahana biosynthesis hou no ka hoʻomohala ʻana i ka maʻi fetal, ʻoi paha ka hopena o ka hōʻemi ʻana i ka HMG-CoA reductase i ka nui o nā pono o ka hoʻohana ʻana i ka lāʻau i ka wā hāpai. Inā lilo ka mea maʻi i ka wā o ka hoʻohana ʻana i ka lāʻau lapaʻau, pono e hoʻokaʻawale ke ʻano.

ʻAʻole kōkua ʻia ka hoʻohana ʻana o Rosulipu ® no nā keiki ma lalo o 10 mau makahiki.

ʻO ka hopena o ka rosuvastatin ma ka ulu o ka linear (ulu), ke kaumaha o ke kino, BMI (index mass body body) a me ka hoʻomohala ʻana o nā hiʻohiʻona ka lua a kau i ka ʻōhua Tanner i ka makahiki o 10-17 mau makahiki i loiloi wale nō no hoʻokahi makahiki. Ma hope o 52 mau pule o ka hoʻohana ʻana i ka lāʻau lapaʻau haʻawina, ʻaʻohe hopena i ke kiʻekiʻe, ke kaumaha o ke kino, BMI a i ʻole ka ulu ʻana i loaʻa.

Nā hiʻohiʻona o ka noi. Hoʻomaʻa i nā aʻala

I ka poʻe maʻi i loaʻa iā Rosulip ® i nā wai kiʻekiʻe, ʻoi aku ka 40 mg, aia kekahi mau mea o ka proteinuria (hoʻoholo ʻia e hoʻohana ana i kahi kānana hoʻokolohua), ʻo ia ka mea nui o ke kumu tubular a, i ka nui o nā wā, ka pōkole. ʻAʻole hōʻike ʻo Proteinuria i ka maʻi koʻikoʻi a maʻi holomua paha. ʻO nā hanana ʻino mai ka lolo ma ka wā ma hope o ke kūʻaiʻana ua hōʻike pinepine ʻia me ka nui o ka 40 mg.

Hoʻohui i nā io uaua o ka ʻūlū

ʻO nā mea hōʻeha kino o ke iwi, e like me ka myalgia, myopathy, a me ka pinepine ʻole o ka rhabdomyolysis i nānā ʻia i nā mea maʻi me nā hopena āpau o Rosulip ®, ma ka nui o nā dosis nui aʻe o 20 mg. Ke hoʻohana nei i ka ezetimibe i hui pū me ka HMG-CoA reductase inhibitors, hōʻike pinepine nā hihia o rhabdomyolysis i hōʻike pinepine ʻia. ʻAʻole hiki ke hoʻokele ʻia ka hiki ke hoʻopili ʻia ka pharmacodynamic, a no laila e hoʻohana pono ʻia kēia hoʻohui me ka makaʻala.

E like me ka hoʻohana ʻana o nā HMG-CoA reductase inhibitors, nā hihia o rhabdomyolysis e pili ana me ka hoʻohana ʻana o Rosulipu ® i ka wā kūʻai aku ma hope o ka mālama ʻana i nānā pinepine ʻia me kahi maʻi no 40 mg. Aia nā hōʻike o nā hihia hōʻemi o ka necrotizing myopathy, ka mea i hōʻike ʻia e ka maʻi hōʻeuʻeu ʻana me ka hoʻonui ʻana i ka haʻalulu palupalu a me ka hoʻonui ʻana i nā pae CPK i ka wā o ka mālama ʻana a ma hope o ka mālama ʻana me nā statins, e komo pū me rosuvastatin. I kēia hihia, ʻo ka noi ʻana o ka neuromuscular a me nā noi serological, pono e hoʻolilo ʻia ka lāʻau me ka immunosuppressive i nā lāʻau lapaʻau.

ʻO ka hoʻoholo ʻana i ka pae o CPK

ʻAʻole hiki ke ana ʻia ka pae o ka CPK ma hope o ka nui o ka hoʻoikaika kino a i ʻole ke kumu o nā kumu ʻē aʻe i hiki ke hoʻonui i ka CPK, e hōʻole i ka wehewehe ʻana i nā hopena. Inā hoʻonui hoʻonui ʻia nā pae mua o ka CPK (> 5 mai ka palena kiʻekiʻe o ke kumu), pono e hana ʻia kahi hōʻoia hou ma loko o nā lā 5-7. Inā hōʻoia ka hopena o ka loiloi hoʻihoʻi mua i ka pae mua> 5 mai luna o ka palena kiʻekiʻe o ke ʻano, ʻaʻole pono e hoʻomaka ka mālama ʻana.

E hoʻohana ʻia ʻo Rosulip ®, e like me nā mea ʻē aʻe o ka HMG-CoA reductase, me ka makaʻala ʻana i nā mea maʻi me nā mea e pili ana i ka hoʻomohala ʻana i ka myopathy / rhabdomyolysis. Aia kēia mau mea:

lawelawe inoa ʻole
hypothyroidism
ka hele ʻana ma kahi moʻo a pilikino ʻohana paha o ka maʻi ʻōiwi ʻōpiopio.
ka mōʻaukala o ka myotoxicity i kumu e ka HMG-CoA reductase inhibitors a fibrates paha,
inu waiʻawa
makahiki> 70 mau makahiki
nā kūlana i hiki ke alakaʻi i ka hoʻonui ʻana i ka pae o ka lāʻau i ka pulu,
ka manawa like ʻole o nā fibrates.

No kēlā mau maʻi āpau, pono ia e hoʻohālikelike i ka hōʻeha a me ka pōmaikaʻi inā ke hoʻohana ʻana i ka lāʻau lapaʻau, ʻōlelo pū ʻia nā mea mālama lapaʻau.

I ka wā mālama

Hoʻomaʻamaʻa ʻia ka poʻe maʻi i ka pono e hōʻike koke i ka ʻeha ʻana o ka naʻau, nāwaliwali o ka naʻau, a i ʻole he nāwaliwali, ʻoi loa inā ua hele pū ʻia lākou me ka malaise a me ka mai. I kēlā mau maʻi maʻi, pono e hoʻoholo ʻia nā pae CPK. He pono e ho'ōki i ka mālama ʻana inā inā māhuahua ka pae o ka CPK (> 5 mai VMN) a inā i hōʻeha ʻia nā hōʻeha o nā uaua a hōʻeha i ka pilikia ma kēlā me kēia lā (ʻoiai inā ka pae o CPK ≤ 5 mai VMN). Inā hele paha nā ʻōuli a hoʻi mai ka pae o CPK i ka maʻamau, Rosulip ® a i ʻole kekahi mea hoʻoweliweli hou o HMG-CoA reductase hiki ke hoʻāʻo hou ʻia, akā ma ka liʻiliʻi ʻokoʻa ma lalo o ka nānā pono ʻana. ʻAʻole kia pono ka mālama ʻana i nā pae kiʻekiʻe o ka CPK i nā maʻi me ka ʻole o nā hōʻailona i luna.

Eia naʻe, he nui ka hoʻonui ʻana o ka myositis a me myopathy i ʻike ʻia i nā mea maʻi e hoʻohana ana i nā HMG-CoA reductase inhibitors me nā derivatives acid fibroic, me ka gemfibrozil, cyclosporin, kaomi nikotinic, nā mānoanoa antifungal azole, nā protease inhibitor a me nā antibiotics macrolide. Hoʻonui ka Gemfibrozil i ka loaʻa o ka myopathy aʻo ka mea hoʻohana me kekahi mau HMG-CoA reductase inhibitors, no laila, ʻaʻole i kauoha ʻia ʻo Rosulip ® no ka hoʻohana pū ʻana me gemfibrozil. ʻO nā hopena pōmaikaʻi o nā loli hou e pili ana i nā pae lipid me ka hoʻohana pinepine ʻana o Rosulipu ® me nā fibrates a i ʻole niacin e hoʻohālikelike ʻia i nā hopena pōpilikia inā hoʻohana ʻia ia ʻano hui. ʻO ka hoʻohana like ʻana o Rosulipu® ma kahi o 40 mg o fibrates e contraindicated.

Pono e hoʻohana ʻia ka Rosulip ® me ka mālama ʻana i nā poʻe maʻi me nā mea e kōkua ana i ka hoʻomohala ʻana i ka myopathy, e like me ka renal gagal, ke kiʻekiʻe ʻana o ka makahiki, ka hypothyroidism, a i nā hanana paha e hoʻonui ai ka manaʻo o ka lāʻau i ka plasma.

ʻAʻole pono ke hoʻohana ʻia ʻo Rosulip ® i nā mea maʻi me nā maʻi koʻikoʻi, nā hopena koʻikoʻi e komo ai i ka hoʻomohala ʻana i ka myopathy a i ʻole ka hoʻonui ʻana i ka hoʻoulu ʻana i ka pilikia ʻoi aku ka maʻi ma muli o ka rhabdomyolysis (e like me sepsis, hypotension, surgery nui, trauma, metabolic koʻikoʻi, endocrine a me nā electrolyte hana ʻino a me nā hana makehewa ʻole.

Pilikia ka pehu

E like me nā HMG-CoA reductase inhibitors, pono iā Rosulip ® me ka makaʻala loa i nā mea maʻi me ka mōʻaukala o nā waiʻona a me / a mai nā maʻi ʻeha.

Noea ʻia e nānā i ka hana ate ma mua o ka hoʻomaka ʻana o ka hoʻohana ʻana i ka lāʻau lapaʻau a ma hope o 3 mau mahina o ka mālama ʻana. Inā ʻaʻoleʻoi aku ka pae o ka transaminases ma ka serum koko ma mua o ʻekolu mau manawa i luna o ka palena kiʻekiʻe o ka maʻamau, pono e hoʻohana ʻia ka hoʻohana ʻana o Rosulip. Hōʻeha ka pilikia o ka puʻuwai maʻi (ʻoi aku ka hoʻonui i ka transaminases hepatic) i ka wā ma hope o ke kūʻai ʻana i hōʻike pinepine ʻia me ka nui o ka 40 mg.

I ka poʻe maʻi me ka hypercholesterolemia kūmole i hoʻokumu ʻia e ka hypothyroidism a i ʻole nephrotic syndrome, pono e mālama mua ʻia ka mālama ʻana i ka maʻi lalo.

I nā noiʻi o pharmacokinetics, ua ʻike ʻia ka nui o ka hoʻolaha ʻana i nā ʻōnaehana i nā maʻi o ka lāhui Mongoloid i hoʻohālikelike ʻia me nā ʻelele o ka lāhui Europa.

ʻAʻole hoʻohana ʻia ka hoʻohana like ʻana o ka lāʻau me nā inhibitor ʻo protease.

ʻO nā mea maʻi me ka galactose intolerance maʻamau i loaʻa ʻole, ka hemahema o Lapp lactase a i ʻole malabsorption glucose-galactose.

ʻO ka maʻi māmā interstitial

Ua hōʻike ʻia nā hihia ʻoi e pili ana i ka maʻi umauma interstitial me kekahi mau statins, ʻoi aku hoʻi i ka hana o ka hopena lōʻihi. ʻO nā hōʻailona o ka huakaʻi e pili ana i ka pōkole o ka hanu, kōmū hua ʻole, a me ka nui o ke kaumaha i ke ʻano maʻamau (pau a me ka hoʻoluhi, ke kaumaha o ke kau, a me ke maʻi). Inā kānalua ka mea maʻi i hoʻomohala i ka maʻi ʻōpū interstitial, pono e hoʻohana ʻia ka hoʻohana o nā statins.

E like me nā poʻe HMG-CoA reductase inhibitors, kahi piʻi i HbA1c a me nā pae serum glucose i nānā me ka rosuvastatin. I kekahi mau hihia, hiki i kēia mau ʻōmole ke keu aku i ka palena no ka maʻi o ka maʻi maʻi, ʻoi aku hoʻi i nā mea maʻi me ka nui o ka ulu ʻana o ka maʻi maʻi.

Na keiki he 10 a 17 mau makahiki

ʻO ka hiki ke alakaʻi i ka hopena i ka wā e lawe ana i nā kaʻa a i ʻole nā hana ʻē aʻe

ʻAʻole i hoʻokō ʻia kahi hōʻike o ka hopena o ka rosuvastatin ma ka hiki ke alakaʻi i nā kaʻa a hana paha me nā mīkini ʻē aʻe.

Eia nō naʻe, i hāʻawi i kāna mau huahana pharmacodynamic, ʻaʻole hiki i ka Rosulip ® ke hopena i ka hopena o ka hopena i ka wā e holo ana a i ʻole e hana pū me nā mīkini ʻē aʻe. Eia nō naʻe, pono e hāpai i ka noʻonoʻo e loaʻa ka hilahila i ka wā o ka hōʻola.

Nā ʻōkuhi no ka hoʻohana ʻana iā Rosulip: kaʻina a me ka maʻi

Lawe ʻia ʻo Rosulip. E hoʻopau ʻia ka papa ʻaina piha, me ka ʻole o ka ʻāʻī ʻana a me ka ʻaʻa ʻole, a holoi ʻia me ka wai. Hiki ke lawe ʻia kahi mea hoʻihoʻi waha-lipid i kēlā me kēia manawa o ka lā, ʻaʻohe mea e pili ana i ka ʻai o ka meaʻai.

Ma mua o ka lawe ʻana i ka lāʻau lapaʻau, pono ka mea maʻi e huli i kekahi meaʻai maʻamau me kahi haʻahaʻa o Chs, me ia e hahai ai i nā papa holoʻokoʻa. Koho ke kauka i ka mahele o ka rosuvastatin pakahi, ma muli o nā hōʻike a me ka pono o ka mālama ʻana, a mālama pū ʻia i nā hōʻike i kēia manawa i nā pae lipid kiko.

ʻO nā mea maʻi ʻaʻole i loaʻa i nā statins a i ʻole e lawe ʻia mai ka lawe ʻana i nā HMG-CoA reductase inhibitors e aʻo ʻia e lawe i ka Rosulip 1 mau lā i kēlā me kēia lā ma kahi kīnā o 5 a 10 mg paha. Ke koho nei ke koho o ka hopena mua ka mea e alakaʻi ʻia, alakaʻi ʻia e kēlā me kēia pae o ka cholesterol a me ka noʻonoʻo e pili ana i ka hiki ʻana mai o nā hoʻopiʻi cardiovascular, a me ka hopena o ka hopena e hikiʻole i nā hopena kūpono.

Inā pono, e hoʻonui i ka dosis 4 mau wiki ma hope o ka hoʻomaka ʻana o ke papa. Ma hope o ka lawe ʻana i kahi kaʻe o ka nui o ka pā mua no ka mau hebedoma 4, ʻoi aku ka hoʻonui hou aʻe i 40 mg i ʻae ʻia me ka hypercholesterolemia kino a me ka hōʻemi ʻana i ka loaʻa ʻana o nā ʻōwili o ka maʻi maʻi (ma ka hapanui i nā mea maʻi me ka hypercholesterolemia familial) ma ka hihia inā ʻaʻole hiki ke hoʻokō ʻia ka hopena i makemake ʻia i ka wā e hoʻohana ai dosis o 20 mg. I loko o ka manawa o kēia hoʻonui o ka nui o ka wai, a me ka hoʻokō ʻia o Rosulip ma hope o kahi o 40 mg, pono nā mea maʻi i lalo o ka mākaʻikaʻi ʻana o ka ʻomaʻi.

I kuhi ʻia nā mea kūʻokoʻa i ka myopathy, i ke kau ʻana i nā papa o 10 a me 20 mg, ua kauoha ʻia e lawe iā Rosulip i kahi kinapo o kēlā me kēia lā o 5 mg. I mua o nā mea e hōʻike ai i kahiʻano i ka wā e loaʻa ai kaʻu myopathy, ʻo ke koho ʻana i ka lāʻau lapaʻau ma kahiʻaʻaʻa o 40 mg ua contraindicated.

I nā maʻi me ka hōʻemi ʻana o nā hana kūpono o nā pūpū (CC ma mua o 60 ml / min), ʻo ka hopena mua o Rosulip me 5 mg.

ʻO ka ʻōmua mua no nā maʻi maʻi (ma mua o 65) he 5 mg.

No nā luna o ka lāhui Mongoloid, ua hoʻohālikelike ʻia nā papa rosulip ma ke kūkaʻi o 40 mg, i ka wā e hoʻohana ai i ka 10 mg a me nā papaʻaila 20 mg, pono e hoʻomaka i ka lawe ʻana i ka pā o 5 mg.

Ma hope o 2 mau hebedoma no ka mālama ʻana a / a i ʻole hōʻino i ke kua o ka hoʻonui o ka nui, pono ia e nānā i ka lipid metabolism, a inā pono, hoʻoponopono ʻia ka ʻopopau.

Nā hopena hopena

ʻO nā kolohe i hoʻopaʻa ʻia ma ka wā o ka mālama ʻana me Rosulip i maʻalahi ka maʻalahi a me ka transient. ʻO ke alapine o nā hopena ʻokoʻa ma muli o ka lawe ʻana i ka rosuvastatin he hilinaʻi kūlike.

musculoskeletal system: pinepine - myalgia, panoke - myopathy (meʻuʻu myitisitis) a me ka rhabdomyolysis me ka hoʻomohala ʻana o ka hiki ʻana o ka pilikia renal a ʻole ʻole, me ka ʻike ʻole ʻole - kūlohelohe ʻorotrotizing myopathy, nui-hilinaʻi nui ma ka pae o ka creatine phosphokinase (CPK) (nānā i kahi liʻiliʻi ka nui o nā mea maʻi, i ka hapanui o nā maʻi he asymptomatic, kīnā ʻole a me ka pōkole), loaʻa pinepine loa - arthralgia,
ka pānaʻi ʻana: pinepine - ka ʻeha o ka ʻōpū, ke kala, ka constipation, pinepine - i ka helehelena, ka maʻi uila, ka liʻiliʻi a me ka hana ʻana o nā transaminases hepatic, ʻaʻole loa - pancreatitis, loaʻa pinepine iā ia - hepatitis, jaundice, me kahi ʻike pinepine ʻole - ʻeha,
ʻūnaehana nūnaehana: pinepine - dizziness, headache, ʻeha loa - hoʻonaninani / nalowale hoʻomanaʻo, polyneuropathy,
ka maʻi kūwaho: jarang hoʻi - ke ʻano o ka hypersensitivity (me ka edion angioneurotic),
ʻili a me nā hiʻona ʻōpala: pinepine - - wikiwiki, ʻehaʻeha o ka ʻili, urticaria, me kahi ʻano ʻike ʻole - ʻo ka maʻi Stevens-Johnson,
ʻ systemnaehana hanu: ʻike pinepine ʻole - ka manawa o ka hanu, kōmole,
urinary system: proteinuria (i ka wā e loaʻa ana i kahi kaila o 10-20 mg - emi mai ka 1% o nā mea maʻi, i ka wā e loaʻa ai ka paʻu o 40 mg - e pili ana ia 3%), ka mea i ka hoʻemi ʻia a i ʻole hoʻi i ka wā o ka mālama ʻana a ʻaʻole ia e manaʻo i ka hoʻomohala ʻana a i ka hoʻomālamalama o kahi maʻi kidney ma mua. loa loa - hematuria,
nā mea ʻē aʻe: pinepine - asoxic syndrome, līpeke loa - gynecomastia, me ka loaʻa ʻole o ka ʻike - nā hana hoʻokūkū o ka kele thyroid.
nā mākaʻina labina: jarang - thrombocytopenia, me ka ʻike ʻole - hyperglycemia, piʻi nui o bilirubin, hemoglobin glycosylated, hoʻonui i ka hana o ka alkatine phosphatase, gamma glutamyl transpeptidase.

I ka wā o ka mālama ʻana me kekahi mau statins, ua hōʻike pū ʻia nā hopena ʻino loa: me kahi ʻike ʻole - ʻo ka hiamoe o ka hiamoe (me ka ʻike ʻole ʻana i ka pō a me nā insomnia), ke kaumaha, ka hana hewa, nā hihia kūʻokoʻa - maʻi maʻi interstitial (like me ka hoʻohana mau ʻana).

ʻŌpū a me ka lactation

I ka wā hāpai a ma ka umauma, ua contraindicated ka hoʻohana ʻana o Rosulip.

Inā loaʻa ka hopena hapai i ka wā o ka hōʻola, pono e hoʻokuʻu koke i ka lāʻau. Pono nā wahine o ka hānau keiki ʻana e hoʻohana i nā ʻukena kūpono i ka wā mālama. Ma muli o ke kumu nui o Chs a me kāna mau huahana biosynthesis i mea nui no ka hoʻomohala ʻana o ka ʻōpio, ʻo kahi hoʻoweliweli kūpono paha o ka hoʻoneʻe ʻana o ka HMG-CoA reductase ma mua o nā pono o ka lāʻau lapaʻau.

Pono nā wahine e pono ke hoʻohana iā Rosulip i ka wā lactation e ʻokiʻoki i ka umauma, no ka mea ʻaʻohe ʻikepili ma ka kola o rosuvastatin me ka waiū umauma.

Hoʻohana i ke wā kamaliʻi

I ka lahui o ka pediatric, ʻaʻole i ʻike ʻia ka maikaʻi a me ka palekana o Rosulip. Loaʻa ka ʻike no ka hoʻohana ʻana i ka rosuvastatin no kēia ʻano o nā mea maʻi i ka helu liʻiliʻi o nā mea maʻi ʻo 8 mau makahiki a ʻoi aku paha me kahi ʻano homozygous o ka hypercholesterolemia hoʻoilina.

ʻAʻole pono nā keiki a me nā ʻōpio ma lalo o ka 18 makahiki i ka lāʻau.

Me ka hana pūnāwai paʻa ʻole

I mua o kahi hōʻeha nui o ka hakahaka o ka renal (CC ma lalo o 30 ml / min), ua hoʻohana ʻia ka hoʻohana ʻana o Rosulip i kekahi mea he wai.

Ua hoʻohālikelike ʻia nā papa 40 mg i nā hihia o ka hōʻemi o ka pilikia o ka renal (CC ma mua o 60 ml / min), me kahi haʻahaʻa haʻahaʻa - pono e hoʻohana me ka akahele.

Pono e mālama ʻia nā papa o 10 a me 20 mg no ka hina ole i ka pale. No nā mea maʻi me ka hōʻemi haʻahaʻa kūpono o nā pūlima (CC ma mua o 60 ml / min), ʻo ka hopena mua o Rosulip me 5 mg.

Me ka hana pūpū hemahema

Wahi a nā ʻōlelo kuhikuhi, ua contraindicated ʻo Rosulip i ka hele ʻana o kahi hana ikaika o ka maʻi o ka ate, me ka hoʻomau mau ʻana i ka hana serum o nā transaminases a me ka hoʻonui ʻana i kā lākou hana ma mua o VGN ma mua o 3 mau manawa. Inā loaʻa he moʻolelo o ka maʻi o ka ate, pono e hoʻohana ʻia ka lāʻau lapaʻau me ka mālama.

Nā Hōʻikeʻike iā Rosulip

Wahi a kekahi mau loiloi, hoʻomaikaʻi maoli ʻo Rosulip i nā kiʻekiʻe o ka kolamu ma ke koko, no laila e hoʻohaʻahaʻa i ka nui o ka hoʻomohala ʻana i ka atherosclerosis a me nā maʻi cardiovascular. Eia nō naʻe, i mea e hoʻokō ai i nā hopena lapaʻau maikaʻi, ʻo ka mea maʻi e loaʻa ana i ka lāʻau lapaʻau e tūtū ana e mālama i ka pae kūpono o ka hoʻoikaika kino a ʻike pono i ka meaʻai kūpono.

ʻO nā meaʻinoʻole o ka lipid-hoʻohaʻahaʻa i loko o kahi papa inoa o nā contraindications a me ka hoʻomohala ʻana o nā hopena ʻaoʻao, ʻoi nui ka nausea a me ka ʻōpū. Eia nō kekahi, nui ka poʻe maʻi e hoʻopiʻi e pili ana i ke kumukūʻai nui o Rosulip.